Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hormone Receptor Positive Metastatic Breast Cancer”

391 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 391 results

Large-scale testing (Phase 3)Active Not RecruitingNCT05654623
What this trial is testing

Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

Who this might be right for
Advanced Breast Cancer
Pfizer 624
Large-scale testing (Phase 3)Study completedNCT01602380
What this trial is testing

A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.

Who this might be right for
Hormone Receptor Positive Breast Cancer
AstraZeneca 462
Not applicableStudy completedNCT03280303
What this trial is testing

Palbociclib in Real World Practice

Who this might be right for
Advanced Breast CancerMetastatic Breast Cancer
Pfizer 1,285
Testing effectiveness (Phase 2)Ended earlyNCT06851442
What this trial is testing

Clinical Trial of Evaluating TQB3912 Tablets Combined With Fulvestrant Injection±TQB3616 Capsules for Locally Advanced or Metastatic Hormone Receptor(HR)-Positive and Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

Who this might be right for
Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 8
Large-scale testing (Phase 3)Looking for participantsNCT07062965
What this trial is testing

Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

Who this might be right for
Breast Cancer
Pfizer 400
Testing effectiveness (Phase 2)UnknownNCT03204734
What this trial is testing

Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen at Least 2nd Line in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Zhejiang Cancer Hospital 132
Large-scale testing (Phase 3)Looking for participantsNCT07060807
What this trial is testing

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

Who this might be right for
Breast Neoplasms
Merck Sharp & Dohme LLC 1,000
Very early researchNot Yet RecruitingNCT07671092
What this trial is testing

Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC

Who this might be right for
Metastatic Urothelial CarcinomaBreast CancerTNBC - Triple-Negative Breast Cancer+2 more
RayzeBio, Inc. 40
Large-scale testing (Phase 3)Study completedNCT00295620
What this trial is testing

Secondary Adjuvant Long Term Study With Arimidex

Who this might be right for
Breast Cancer
AstraZeneca 3,484
Testing effectiveness (Phase 2)UnknownNCT04088110
What this trial is testing

Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer

Who this might be right for
Breast Cancer FemaleHER2-positive Breast CancerHormone Receptor Positive Malignant Neoplasm of Breast+3 more
Fuzhou General Hospital 77
Testing effectiveness (Phase 2)Study completedNCT02344550
What this trial is testing

Study of GnRH-A [Leuprorelin(Lorelin Depot] Plus Leterozole +/- Everolimus for Premenopausal Women With Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Asan Medical Center 137
Early research (Phase 1)Study completedNCT05064085
What this trial is testing

Capecitabine In Combination With Cemiplimab In Patient With Metastatic Breast Cancer

Who this might be right for
Hormone Receptor-positive Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute 13
Testing effectiveness (Phase 2)WithdrawnNCT02853071
What this trial is testing

Efficacy and Safety of Estracyt® in Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Centre Hospitalier Universitaire de Besancon
Large-scale testing (Phase 3)Study completedNCT00022672
What this trial is testing

Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® Alone in Patients With Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 208
Early research (Phase 1)WithdrawnNCT04498520
What this trial is testing

Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8+32 more
Pamela Munster
Testing effectiveness (Phase 2)Ended earlyNCT04789668
What this trial is testing

Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Hematopoietic and Lymphoid Cell Neoplasm+11 more
M.D. Anderson Cancer Center 8
Testing effectiveness (Phase 2)Study completedNCT00602043
What this trial is testing

F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer

Who this might be right for
Estrogen Receptor-positive Breast CancerProgesterone Receptor-negative Breast CancerProgesterone Receptor-positive Breast Cancer+2 more
National Cancer Institute (NCI) 20
Testing effectiveness (Phase 2)Study completedNCT03227328
What this trial is testing

CDK4/6-inhibitor or Chemotherapy, in Combination with ENDOcrine Therapy, for Advanced Breast Cancer / KENDO

Who this might be right for
Hormone Receptor Positive Breast CancerMetastatic Breast CancerHormone Receptor Negative Breast Cancer
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 52
Large-scale testing (Phase 3)Study completedNCT01160211
What this trial is testing

Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer

Who this might be right for
Neoplasms, Breast
Novartis Pharmaceuticals 369
Not applicableLooking for participantsNCT07227831
What this trial is testing

A Ph II Study of the TheraBionic P1 Device in Subjects With Hormone Positive Breast Cancer

Who this might be right for
HER2-negative Breast CancerHormone Receptor Positive TumorAdvanced Breast Cancer+1 more
Barbara Ann Karmanos Cancer Institute 82
Next Page